FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) Director Not Standing for Reelection
On May 18, 2017, Evan Jones, a member of the Board of Directors (the “Board”) of Fluidigm Corporation (the “Company”) notified the Company that he will not stand for reelection at the Company’s next annual meeting of stockholders (the “Annual Meeting”). Mr. Jones will continue to serve as director until the expiration of his term.
In connection with Mr. Jones’ decision not to stand for re-election to the Board at the Annual Meeting, the Board, on May 23, 2017, resolved to reallocate a Class III director (with a term expiring at the 2019 annual meeting of stockholders) to Class I (with a term expiring at the 2017 annual meeting of stockholders). Accordingly, on May 23, 2017, Nicolas Barthelemy, age 51, stepped down as a Class III director and was immediately reappointed to the Board as a Class I director. Concurrently, the number of Class I seats was increased by one to three seats, and the number of Class III seats was reduced by one to two seats. Mr. Barthelemy continues to serve on the Company’s compensation committee and was, concurrently with his appointment to Class I, appointed to serve on the audit committee.
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers. FLUIDIGM CORPORATION (NASDAQ:FLDM) Recent Trading Information
FLUIDIGM CORPORATION (NASDAQ:FLDM) closed its last trading session down -0.57 at 4.89 with 159,906 shares trading hands.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers. FLUIDIGM CORPORATION (NASDAQ:FLDM) Recent Trading Information
FLUIDIGM CORPORATION (NASDAQ:FLDM) closed its last trading session down -0.57 at 4.89 with 159,906 shares trading hands.
